russian grey
𝐋𝐃𝐀𝐑 𝐢𝐬 𝐚 𝐜𝐡𝐨𝐢𝐜𝐞
- Joined
- Nov 3, 2026
- Messages
- 35
- Online time
- 4h 56m
- Reputation
- 333
Hello everyone. In this thread, I will explain the mechanism of action of Abaloparatide (Abalo) and how it can potentially lengthen the mandible.
What is Abaloparatide?
Abaloparatide is a synthetic peptide analog of parathyroid hormone-related protein (PTHrP). It is used for the treatment of osteoporosis. It belongs to anabolic agents, meaning it stimulates new bone formation rather than just suppressing bone resorption.
Mechanism of action
Abalo works through the PTH1R receptor, which is located on the surface of osteoblasts and chondrocytes. PTH1R exists in two forms: RG and R0. The RG form triggers a transient signal via cAMP, which leads to new bone formation. The R0 form gives a prolonged signal, leading to bone resorption and hypercalcemia (elevated blood calcium). Abaloparatide works almost exclusively through the RG form without affecting the R0 form. That is why it provides a powerful anabolic effect with a lower risk of bone loss and hypercalcemia compared to other drugs. In chondrocytes, it also acts through PTH1R activation in the condylar cartilage, supporting proliferation and suppressing premature differentiation. This creates a longer period for cartilage to grow instead of ossifying.
What about the mandible?
Let's move on to the main topic of this thread: how it can affect the mandible.
A study was conducted on 4-week-old male rats, distributed into 14 groups of 5:
· 1 control group (saline)
· 1 MA group (MA = functional appliance for jaw protrusion, received saline)
· 6 drug groups (without MA) receiving daily subcutaneous injections of Abalo at different doses (high 8 mg/kg, medium 800 µg/kg, low 80 µg/kg)
· 6 drug groups + MA. Same doses, but with simultaneous use of the jaw protrusion appliance.
Results: Abalo alone increased condylar length and cartilage thickness while increasing SOX9 and type II collagen expression and decreasing type X collagen (demonstrating that Abalo can keep chondrocytes "younger" and more responsive to load). When combined with MA, the stimulatory effects on cartilage thickening weakened. Abalo alone increased the height of the mandibular body and the width of the jaw angle, while in combination with MA, it increased mandibular body length and alveolar bone width. In vitro, Abalo showed a similar effect to in vivo. In this particular study, Abalo and mechanical loading did not show synergy.
Theoretically, Abaloparatide could also enhance bonesmashing efficiency via PTH1R, since this receptor is also present on osteoblasts.
Conclusion
Theoretically, Abaloparatide can lengthen the mandible in humans, but this has not been proven yet, as it has not been studied in adolescents. Therefore, use it at your own risk.
www.nature.com
@aspiringpslgodess Please read this text, I put a lot of effort into it.What is Abaloparatide?
Abaloparatide is a synthetic peptide analog of parathyroid hormone-related protein (PTHrP). It is used for the treatment of osteoporosis. It belongs to anabolic agents, meaning it stimulates new bone formation rather than just suppressing bone resorption.
Note that Abaloparatide is not approved for adolescents, as its effects on the adolescent body have not been studied.
Abalo works through the PTH1R receptor, which is located on the surface of osteoblasts and chondrocytes. PTH1R exists in two forms: RG and R0. The RG form triggers a transient signal via cAMP, which leads to new bone formation. The R0 form gives a prolonged signal, leading to bone resorption and hypercalcemia (elevated blood calcium). Abaloparatide works almost exclusively through the RG form without affecting the R0 form. That is why it provides a powerful anabolic effect with a lower risk of bone loss and hypercalcemia compared to other drugs. In chondrocytes, it also acts through PTH1R activation in the condylar cartilage, supporting proliferation and suppressing premature differentiation. This creates a longer period for cartilage to grow instead of ossifying.
What about the mandible?
Let's move on to the main topic of this thread: how it can affect the mandible.
A study was conducted on 4-week-old male rats, distributed into 14 groups of 5:
· 1 control group (saline)
· 1 MA group (MA = functional appliance for jaw protrusion, received saline)
· 6 drug groups (without MA) receiving daily subcutaneous injections of Abalo at different doses (high 8 mg/kg, medium 800 µg/kg, low 80 µg/kg)
· 6 drug groups + MA. Same doses, but with simultaneous use of the jaw protrusion appliance.
Results: Abalo alone increased condylar length and cartilage thickness while increasing SOX9 and type II collagen expression and decreasing type X collagen (demonstrating that Abalo can keep chondrocytes "younger" and more responsive to load). When combined with MA, the stimulatory effects on cartilage thickening weakened. Abalo alone increased the height of the mandibular body and the width of the jaw angle, while in combination with MA, it increased mandibular body length and alveolar bone width. In vitro, Abalo showed a similar effect to in vivo. In this particular study, Abalo and mechanical loading did not show synergy.
Theoretically, Abaloparatide could also enhance bonesmashing efficiency via PTH1R, since this receptor is also present on osteoblasts.
Conclusion
Theoretically, Abaloparatide can lengthen the mandible in humans, but this has not been proven yet, as it has not been studied in adolescents. Therefore, use it at your own risk.
The recommended dose is 80 mcg once daily. It is typically injected subcutaneously around the abdomen. You should inject it approximately 5 cm away from the navel (see the reference image for the correct injection site).
Also, change the injection site every time to avoid skin irritation. AND MAKE SURE IT'S A SUBCUTANEOUS INJECTION!
Also, change the injection site every time to avoid skin irritation. AND MAKE SURE IT'S A SUBCUTANEOUS INJECTION!
Local abaloparatide administration promotes in situ alveolar bone augmentation via FAK-mediated periosteal osteogenesis - International Journal of Oral Science
Insufficient alveolar bone thickness increases the risk of periodontal dehiscence and fenestration, especially in orthodontic tooth movement. Abaloparatide (ABL), a synthetic analog of human PTHrP (1–34) and a clinical medication for treating osteoporosis, has recently demonstrated its potential...
www.nature.com
@NotFun
@trav
@Nkq
